DS-103

• Description :

  DS-103 is an inhibitor for HDAC that inhibits HDAC1, HDAC2, HDAC3, HDAC6 and HDAC8 with IC50s of 0.029, 0.123, 0.022, 0.367 and 9.26 μM, respectively. DS-103 inhibits Plasmodium falciparum 3D7 with IC50 of 5.08 μM. DS-103 exhibits cytotoxicity in cells A2780 and Cal27 with IC50 of 1.48 μM and 1.47 μM, reverses Cisplatin (HY-17394) resistance in A2780 and Cal27 with IC50 of 4.62 μM and 2.23 μM. DS-103 exhibits synergistic effect with Cisplatin (HY-17394), enhances Cisplatin-induced apoptosis[1].

• UNSPSC :

  12352005

• Target :

  HDAC; Parasite

• Related Pathways :

  Anti-infection; Cell Cycle/DNA Damage; Epigenetics

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Cancer; Infection

• Smiles :

  O=C(N(CC1=CC=C(C=C1)C(NNCC)=O)CC(NCC2=CC=CC=C2)=O)C3=CC=C(C=C3)N(C)C

• Molecular Formula :

  C28H33N5O3

• Molecular Weight :

  487.59

• References & Citations :

  [1]Stopper D, et al., Exploring Alternative Zinc-Binding Groups in Histone Deacetylase (HDAC) Inhibitors Uncovers DS-103 as a Potent Ethylhydrazide-Based HDAC Inhibitor with Chemosensitizing Properties. J Med Chem. 2025 Feb 27;68 (4) :4426-4452.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  HDAC1; HDAC2; HDAC3; HDAC6; HDAC8